Drug Delivery

Transdermal drug-delivery device company launches human clinical trial

Published in Obesity and Diabetes Week, August 29th, 2005

Dermisonics, Inc., (DMSI), a medical-device company focused upon the development of an ultrasonically assisted transdermal drug-delivery technology, announced that it has initiated preclinical testing of the U-Strip Transdermal Drug Delivery System in anticipation of a human clinical trial designed to test the technology on insulin-dependent, type-2 diabetics.

The company is conducting a pharmacokinetic study of the insulin patch as the first phase of study. Completion of the trial set-up is a prerequisite to testing upon the human volunteers.

The Human Pilot Trial-2 (HPT-2) protocol is designed to test lispro insulin using three different versions...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry